About USCAST

USCAST is part of a global network dedicated to fighting the rise of antibiotic resistance through scientific, educational, and policy-creating activities.

We recognize an increasing need to create a path to evaluate both new and old antibacterial agents in the current context of antibacterial resistance, extent of tissue penetration at the site of infection, and bacterial killing rate at that body site.

Our mission is to work with our global partners, establishing crucial standards for testing and interpreting the activity of antibacterial agents. The standards established by USCAST are intended to provide support for healthcare providers to use the safest and most effective antibacterial agents to save lives.

Unlike other STIC setting organizations, USCAST does not aim to provide comprehensive pathogen-drug breakpoint tables, but rather focuses the expertise of our membership on both generating new evidence and interpreting imperfect existing data to address the most challenging breakpoint controversies.

EXECUTIVE COMMITTEE

Jason M. Pogue, Pharm. D.

Chairman

University of Michigan College of Pharmacy

Sujata M. Bhavnani, Pharm. D., MS

Vice Chair

Institute for Clinical Pharmacodynamics

Paul G. Ambrose, Pharm. D.

Treasurer

Institute for Clinical Pharmacodynamics

David R. Andes, MD

University of Wisconsin

Ronald N. Jones, MD

Emeritus Member

Thomas P. Lodise, Pharm. D., Ph.D.

Albany College of Pharmacy & Health Sciences

Helio S. Sader, MD, Ph.D.

Element Iowa City (JMI Laboratories)

MEMBERS

John S. Bradley, MD

University of California San Diego Rady Children’s Hospital

Alexander J. Lepak, MD

University of Wisconsin School of Medicine and Public Health

Emil P. Lesho, DO

Infectious Diseases Unit Rochester Regional Health

Erin K. McCreary, Pharm. D.

University of Pittsburgh Medical Center

Robert R. Rennie, Ph.D.

University of Alberta Hospital

Stefan Riedel, MD, Ph.D.

Harvard Medical School

Keith A. Rodvold, Pharm. D.

University of Illinois at Chicago College of Pharmacy

Michael J. Rybak, Pharm. D., Ph.D.

Wayne State University

Marc Scheetz, Pharm. D., MSc

Midwestern University

ADVISORS

Olga Lomovskaya, Ph.D.

Qpex Biopharma

Denver T. Niles, MD

Texas Children's

Ryan K. Shields, Pharm. D.

University of Pittsburgh Medical Center

Judith Steenbergen, Ph.D.

Scientific and Medical Affairs Consulting (SMAC)

Our Process

The below schematic represents the USCAST process for STIC assessment. While our membership ultimately votes on STIC, interested stakeholders are a critically important part of our STIC-setting process. We encourage interested parties to participate in our annual virtual meetings at which STIC recommendations are initially presented and provide feedback on the proposals. Final STIC recommendations will be based on objective consideration of any feedback received.

1
Executive Committee Prioritizes STIC for Assessment
2
Working Group Formed
3
Draft Proposal/ Presentation
4
Presented to Executive Committee
5
Presented to Full Membership
6
Full Membership Vote
7
Public Comment Period
8
Review Public Feedback
9
Final Vote and STIC Set

While the executive committee is responsible for the final decisions on what STIC to prioritize for assessment, we encourage feedback from our members and the community at large regarding clinically important STIC that need to be reassessed. If you have a STIC recommendation for USCAST to consider, please contact us here.